

Crystal Structure of Nitric Oxide Synthase Bound to Nitric Oxide Inactivation Mechanism

Biochemistry

40, 13448-13455

DOI: [10.1021/bi010957u](https://doi.org/10.1021/bi010957u)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Binding of L-Arginine and Imidazole Suggests Heterogeneity of Rat Brain Neuronal Nitric Oxide Synthase. <i>Biochemistry</i> , 2002, 41, 7819-7829.	1.2	19
2	First Non- α -Amino Acid Guanidines Acting as Efficient NO Precursors upon Oxidation by NO-Synthase II or Activated Mouse Macrophages. <i>Biochemistry</i> , 2002, 41, 9286-9292.	1.2	23
3	29. <i>Bioinorganic chemistry. Annual Reports on the Progress of Chemistry Section A</i> , 2002, 98, 593-614.	0.8	3
4	The antithyroid agent 6-n-propyl-2-thiouracil is a mechanism-based inactivator of the neuronal nitric oxide synthase isoform. <i>Archives of Biochemistry and Biophysics</i> , 2002, 407, 83-94.	1.4	4
5	N-Aryl N-Hydroxyguanidines, A New Class of NO-Donors after Selective Oxidation by Nitric Oxide Synthases: Structure-Activity Relationship. <i>Journal of Medicinal Chemistry</i> , 2002, 45, 944-954.	2.9	55
6	7-Methoxy-1H-indazole, a new inhibitor of neuronal nitric oxide synthase. <i>Acta Crystallographica Section C: Crystal Structure Communications</i> , 2002, 58, 688-690.	0.4	9
7	Conformational Changes in Nitric Oxide Synthases Induced by Chlorzoxazone and Nitroindazoles: Crystallographic and Computational Analyses of Inhibitor Potency. <i>Biochemistry</i> , 2002, 41, 13915-13925.	1.2	63
8	Cyanide binding study of neuronal nitric oxide synthase: effects of inhibitors and mutations at the substrate binding site. <i>Journal of Inorganic Biochemistry</i> , 2003, 95, 25-30.	1.5	3
9	Implications of protein flexibility for drug discovery. <i>Nature Reviews Drug Discovery</i> , 2003, 2, 527-541.	21.5	640
10	Two Modes of Binding of N-Hydroxyguanidines to NO Synthases: First Evidence for the Formation of Iron-N-Hydroxyguanidine Complexes and Key Role of Tetrahydrobiopterin in Determining the Binding Mode. <i>Biochemistry</i> , 2003, 42, 3858-3867.	1.2	16
11	Computer Modeling of Selective Regions in the Active Site of Nitric Oxide Synthases: Implication for the Design of Isoform-Selective Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 5700-5711.	2.9	69
12	Inhibitory effects and spectral interactions of isomeric methoxyindazoles on recombinant nitric oxide synthases. <i>Nitric Oxide - Biology and Chemistry</i> , 2003, 9, 86-94.	1.2	8
13	Binding Structures and Potencies of Oxidosqualene Cyclase Inhibitors with the Homologous Squalene-Hopene Cyclase. <i>Journal of Medicinal Chemistry</i> , 2003, 46, 2083-2092.	2.9	47
14	Structural Basis for the Specificity of the Nitric-oxide Synthase Inhibitors W1400 and N-Propyl-L-Arg for the Inducible and Neuronal Isoforms. <i>Journal of Biological Chemistry</i> , 2003, 278, 45818-45825.	1.6	66
15	The bioinorganic chemistry of iron in oxygenases and supramolecular assemblies. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 3569-3574.	3.3	312
16	Synthesis, Pharmacological Study and Modeling of 7-Methoxyindazole and Related Substituted Indazoles as Neuronal Nitric Oxide Synthase Inhibitors. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2003, 18, 195-199.	2.5	8
17	Evidence of Two Distinct Oxygen Complexes of Reduced Endothelial Nitric Oxide Synthase. <i>Journal of Biological Chemistry</i> , 2004, 279, 19824-19831.	1.6	31
18	Structural basis for dipeptide amide isoform-selective inhibition of neuronal nitric oxide synthase. <i>Nature Structural and Molecular Biology</i> , 2004, 11, 54-59.	3.6	75

#	ARTICLE	IF	CITATIONS
19	Alternative nitric oxide-producing substrates for no synthases. <i>Free Radical Biology and Medicine</i> , 2004, 37, 1105-1121.	1.3	43
20	Importance of valine 567 in substrate recognition and oxidation by neuronal nitric oxide synthase. <i>Journal of Inorganic Biochemistry</i> , 2004, 98, 1200-1209.	1.5	6
21	Analysis of the kinetics of CO binding to neuronal nitric oxide synthase by flash photolysis: dual effects of substrates, inhibitors, and tetrahydrobiopterin. <i>Journal of Inorganic Biochemistry</i> , 2004, 98, 1210-1216.	1.5	7
22	Drug-like properties: guiding principles for design " or chemical prejudice?. <i>Drug Discovery Today: Technologies</i> , 2004, 1, 189-195.	4.0	71
23	Relationship between the structure of guanidines and N-hydroxyguanidines, their binding to inducible nitric oxide synthase (iNOS) and their iNOS-catalysed oxidation to NO. <i>FEBS Journal</i> , 2005, 272, 3172-3183.	2.2	15
24	Structure and activity of NO synthase inhibitors specific to the L-arginine binding site. <i>Biochemistry (Moscow)</i> , 2005, 70, 8-23.	0.7	2
25	Structure and activity of NO synthase inhibitors specific to the L-arginine binding site. <i>Biochemistry (Moscow)</i> , 2005, 70, 8-23.	0.7	9
26	Prediction of binding modes for ligands in the cytochromes P450 and other heme-containing proteins. <i>Proteins: Structure, Function and Bioinformatics</i> , 2005, 58, 836-844.	1.5	92
27	Endogenous Methylarginines Modulate Superoxide as Well as Nitric Oxide Generation from Neuronal Nitric-oxide Synthase. <i>Journal of Biological Chemistry</i> , 2005, 280, 7540-7549.	1.6	90
28	STRUCTURAL AND FUNCTIONAL DIVERSITY IN HEME MONOOXYGENASES. <i>Drug Metabolism and Disposition</i> , 2005, 33, 10-18.	1.7	49
29	Models and Mechanisms of Cytochrome P450 Action. , 2005, , 1-43.		77
30	Differential Effects of Alkyl- and Arylguanidines on the Stability and Reactivity of Inducible NOS Heme-Dioxygen Complexes. <i>Biochemistry</i> , 2006, 45, 3988-3999.	1.2	11
31	Reactivity of the heme-dioxygen complex of the inducible nitric oxide synthase in the presence of alternative substrates. <i>FEBS Journal</i> , 2006, 273, 180-191.	2.2	10
32	High-valent iron in chemical and biological oxidations. <i>Journal of Inorganic Biochemistry</i> , 2006, 100, 434-447.	1.5	565
33	Synthesis and structural study of tetrahydroindazolones. <i>Tetrahedron</i> , 2006, 62, 11704-11713.	1.0	35
34	Selective Inhibitors of Inducible Nitric Oxide Synthase: Potential Agents for the Treatment of Inflammatory Diseases?. <i>Current Topics in Medicinal Chemistry</i> , 2006, 6, 77-92.	1.0	102
35	Nitric-oxide synthase: A cytochrome P450 family foster child. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2007, 1770, 432-445.	1.1	110
36	Effects of S-nitrosation of nitric oxide synthase. <i>Advances in Experimental Biology</i> , 2007, 1, 151-456.	0.1	4

#	ARTICLE	IF	CITATIONS
37	Inhibitory effects of a series of 7-substituted-indazoles toward nitric oxide synthases: Particular potency of 1H-indazole-7-carbonitrile. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 5962-5973.	1.4	18
38	NG-Aminoguanidines from Primary Amines and the Preparation of Nitric Oxide Synthase Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 924-931.	2.9	26
39	Synthesis of 3-(Tosylalkyl)indazoles and their Desulfonylation Reactions – A New Entry to 3-Substituted Indazoles by an Unprecedented Friedel-Crafts Process. <i>European Journal of Organic Chemistry</i> , 2009, 2009, 3184-3188.	1.2	18
40	Synthesis, reactivity, and NMR spectroscopy of 4,6- and 6,7-difluoro-3-methyl-1H-indazoles. <i>Journal of Heterocyclic Chemistry</i> , 2009, 46, 1408-1412.	1.4	12
41	Fluorinated indazoles as novel selective inhibitors of nitric oxide synthase (NOS): Synthesis and biological evaluation. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 6180-6187.	1.4	46
42	Theoretical calculations of a model of NOS indazole inhibitors: Interaction of aromatic compounds with Zn-porphyrins. <i>Bioorganic and Medicinal Chemistry</i> , 2009, 17, 8027-8031.	1.4	16
43	Chapter 2 Advancements in the Development of Nitric Oxide Synthase Inhibitors. <i>Annual Reports in Medicinal Chemistry</i> , 2009, 44, 27-50.	0.5	30
44	Isoform-specific differences in the nitrite reductase activity of nitric oxide synthases under hypoxia. <i>Biochemical Journal</i> , 2009, 418, 673-682.	1.7	43
45	(±)-Praeruptorin A enantiomers exert distinct relaxant effects on isolated rat aorta rings dependent on endothelium and nitric oxide synthesis. <i>Chemico-Biological Interactions</i> , 2010, 186, 239-246.	1.7	41
46	Trifluoro-3-hydroxy-1H-indazolecarboxylic Acids and Esters from Perfluorinated Benzenedicarboxylic Acids. <i>European Journal of Organic Chemistry</i> , 2010, 2010, 890-899.	1.2	10
47	Comparison of wild type neuronal nitric oxide synthase and its Tyr588Phe mutant towards various l-arginine analogues. <i>Journal of Inorganic Biochemistry</i> , 2010, 104, 1043-1050.	1.5	2
48	Role of Arginine Guanidinium Moiety in Nitric-oxide Synthase Mechanism of Oxygen Activation. <i>Journal of Biological Chemistry</i> , 2010, 285, 7233-7245.	1.6	27
49	Arginine Binding to Human Inducible Nitric Oxide Synthase: An Antisymmetric Funnel Route toward Isoform-Specific Inhibitors?. <i>Journal of Chemical Information and Modeling</i> , 2011, 51, 1325-1335.	2.5	2
50	Constitutively active heat shock factor 1 enhances glucose-driven insulin secretion. <i>Metabolism: Clinical and Experimental</i> , 2011, 60, 789-798.	1.5	7
52	Heteroalicyclic carboxamidines as inhibitors of inducible nitric oxide synthase; the identification of (2R)-2-pyrrolidinecarboxamide as a potent and selective haem-co-ordinating inhibitor. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2011, 21, 3037-3040.	1.0	4
53	Synthesis and biological evaluation of indazole derivatives. <i>European Journal of Medicinal Chemistry</i> , 2011, 46, 1439-1447.	2.6	22
54	The molecular mechanism of mammalian NO-synthases: A story of electrons and protons. <i>Journal of Inorganic Biochemistry</i> , 2011, 105, 127-141.	1.5	70
55	MYST protein acetyltransferase activity requires active site lysine autoacetylation. <i>EMBO Journal</i> , 2012, 31, 58-70.	3.5	101

#	ARTICLE	IF	CITATIONS
56	Selective Monocationic Inhibitors of Neuronal Nitric Oxide Synthase. Binding Mode Insights from Molecular Dynamics Simulations. <i>Journal of the American Chemical Society</i> , 2012, 134, 11559-11572.	6.6	21
57	Vasorelaxant activity of some structurally related triterpenic acids from <i>Phoradendron reichenbachianum</i> (Viscaceae) mainly by NO production: Ex vivo and in silico studies. <i>FÄ-toterapÄ-Äç</i> , 2012, 83, 1023-1029.	1.1	39
58	Mechanism of nitric oxide synthase regulation: Electron transfer and interdomain interactions. <i>Coordination Chemistry Reviews</i> , 2012, 256, 393-411.	9.5	92
59	Investigations on the role of H-bond interactions and H networks in eNOS and nNOS proteins. <i>Bioorganic Chemistry</i> , 2013, 49, 16-23.	2.0	5
60	Structure of NH-benzazoles (1H-benzimidazoles, 1H- and 2H-indazoles, 1H- and 2H-benzotriazoles). <i>Chemistry of Heterocyclic Compounds</i> , 2013, 49, 177-202.	0.6	26
61	Deciphering the Binding of Caveolin-1 to Client Protein Endothelial Nitric-oxide Synthase (eNOS). <i>Journal of Biological Chemistry</i> , 2014, 289, 13273-13283.	1.6	54
62	Identification of Redox Partners and Development of a Novel Chimeric Bacterial Nitric Oxide Synthase for Structure Activity Analyses. <i>Journal of Biological Chemistry</i> , 2014, 289, 29437-29445.	1.6	11
63	Dissecting regulation mechanism of the FMN to heme interdomain electron transfer in nitric oxide synthases. <i>Journal of Inorganic Biochemistry</i> , 2014, 130, 130-140.	1.5	18
64	Re(I) and Tc(I) Complexes for Targeting Nitric Oxide Synthase: Influence of the Chelator in the Affinity for the Enzyme. <i>Chemical Biology and Drug Design</i> , 2015, 86, 1072-1086.	1.5	8
65	Suggested Involvement of PP1/PP2A Activity and De Novo Gene Expression in Anhydrobiotic Survival in a Tardigrade, <i>Hypsibius dujardini</i> , by Chemical Genetic Approach. <i>PLoS ONE</i> , 2015, 10, e0144803.	1.1	43
66	Computational Development of Selective nNOS Inhibitors: Binding Modes and Pharmacokinetic Considerations. <i>Current Medicinal Chemistry</i> , 2015, 22, 2558-2579.	1.2	1
67	Molecular docking and in vitro evaluations of <i>Hippocampus trimaculatus</i> (seahorse) extracts as the anti-inflammatory compounds. <i>International Journal of Bioinformatics Research and Applications</i> , 2016, 12, 355.	0.1	25
68	Inhibitors of Nitric Oxide Synthase: What's up and What's Next?. <i>Current Enzyme Inhibition</i> , 2016, 12, 81-107.	0.3	3
69	Role of Nitric Oxide and Hydrogen Sulfide in the Vasodilator Effect of Ursolic Acid and Uvaol from Black Cherry <i>Prunus serotina</i> Fruits. <i>Molecules</i> , 2016, 21, 78.	1.7	30
70	Nitric oxide synthase and structure-based inhibitor design. <i>Nitric Oxide - Biology and Chemistry</i> , 2017, 63, 68-77.	1.2	38
71	Calmodulin-induced Conformational Control and Allostery Underlying Neuronal Nitric Oxide Synthase Activation. <i>Journal of Molecular Biology</i> , 2018, 430, 935-947.	2.0	14
72	Importance of Val567 on heme environment and substrate recognition of neuronal nitric oxide synthase. <i>FEBS Open Bio</i> , 2018, 8, 1553-1566.	1.0	1
73	Hexachlorobenzene Monooxygenase Substrate Selectivity and Catalysis: Structural and Biochemical Insights. <i>Applied and Environmental Microbiology</i> , 2020, 87, .	1.4	7

#	ARTICLE	IF	CITATIONS
74	Inhibited Nitric Oxide Production of Human Endothelial Nitric Oxide Synthase by Nitrated and Oxygenated Polycyclic Aromatic Hydrocarbons. Environmental Science & Technology, 2020, 54, 2922-2930.	4.6	39
75	A Medicinal Chemistry Perspective on Structure-Based Drug Design and Development. Methods in Molecular Biology, 2012, 841, 351-381.	0.4	14
77	Vasorelaxant and Antihypertensive Effects of (3 ¹)-ursen-12-en-3,28-diol by NO/cGMP System. Letters in Drug Design and Discovery, 2022, 19, .	0.4	0
78	Structure and activity of NO synthase inhibitors specific to the L-arginine binding site. Biochemistry (Moscow), 2005, 70, 8-23.	0.7	5